<p>零售药房连锁企业 CVS Health（CVS）的股价年初至今上涨了 81.86%，尽管其子公司 Omnicare 最近在德克萨斯州申请破产。华尔街对该股票在年末和 2026 年的前景依然持乐观态度。</p>
<h3>享受 TipRanks Premium 50% 折扣，放心投资</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
<p>在最新评级中，摩根大通分析师 Lisa Gill 重申了对该股票的买入评级，并将其目标价从 93 美元上调至 101 美元，暗示约 29% 的上涨空间。作为对医疗保健股票 2026 年展望的一部分，Gill 认为有理由相信，管理医疗公司正接近其盈利周期的低点，这意味着有向上修正的潜力。</p>
<h2><strong>华尔街赞扬未来盈利增长预测</strong></h2>
<p>这位五星级分析师的评论是在 CVS Health 将 2026 财年的指引上调后几天发表的，受到华尔街的热烈欢迎。该健康服务集团指出，预计到 2028 年，其调整后每股收益（EPS）的复合年增长率（CAGR）将在中十几的水平，这与之前的 6% 增长相比更具吸引力。</p>
<p>这家公司总部位于美国罗德岛州，预计将通过其业务的更强利润率来提升业绩，主要得益于其保险部门健康护理福利（HCB）的复苏。</p>
<h2><strong>CVS Health 预计 2026 财年收入低于市场共识</strong></h2>
<p>在 2025 年第三季度，CVS Health 的收入和每股收益超出华尔街预期，尽管有 57.8 亿美元的减记。该公司表示，预计 2025 年将以 “显著的势头” 收尾，并预计 2026 财年收入将达到 4000 亿美元，低于分析师共识的 4183.3 亿美元。</p>
<p>然而，摩根士丹利分析师 Erin Wright 指出，专注于每股收益的 CAGR 预测，该指引 “反响良好”，并且 “明显高于” 之前的估计。Wright 补充说，该药房连锁的 2026 年指引也与之前的评论一致。</p>
<h2><strong>CVS Health 是一个值得购买的好股票吗？</strong></h2>
<p>在华尔街，CVS Health 的股票继续获得强烈买入的共识评级。这是基于过去三个月分析师发布的 17 个买入和一个持有评级。</p>
<p>此外，CVS 的平均目标价为 95.67 美元，意味着从当前交易水平来看有超过 22% 的上涨潜力。</p>

西维斯

<p>CVS Health 的股票年初至今上涨了 81.86%，尽管 Omnicare 已申请破产。华尔街依然保持乐观，摩根大通将目标价上调至 101 美元。CVS Health 预计到 2028 年调整后的每股收益将实现中双位数的年复合增长率，并预计 2026 财年的收入将达到 4000 亿美元。分析师们维持强烈买入的共识，平均目标价为 95.67 美元，显示出超过 22% 的上涨潜力</p>

<p>Retail pharmacy chain CVS Health's (CVS) shares are up 81.86% year-to-date despite subsidiary Omnicare's recent Texas bankruptcy filing. Wall Street remains bullish on the stock into year-end and for 2026.</p>
<div class="lb-trans"><p>零售药房连锁企业 CVS Health（CVS）的股价年初至今上涨了 81.86%，尽管其子公司 Omnicare 最近在德克萨斯州申请破产。华尔街对该股票在年末和 2026 年的前景依然持乐观态度。</p>
</div><h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>享受 TipRanks Premium 50% 折扣，放心投资</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
</div><p>In the latest rating, J.P. Morgan analyst Lisa Gill reaffirmed her Buy rating on the stock and raised her price target from $93 to $101, implying about 29% upside. As part of its 2026 outlook on healthcare stocks, Gill argued that there are reasons to believe that managed care companies are near the low point of their earnings cycles, meaning that there is potential for upward revision.</p>
<div class="lb-trans"><p>在最新评级中，摩根大通分析师 Lisa Gill 重申了对该股票的买入评级，并将其目标价从 93 美元上调至 101 美元，暗示约 29% 的上涨空间。作为对医疗保健股票 2026 年展望的一部分，Gill 认为有理由相信，管理医疗公司正接近其盈利周期的低点，这意味着有向上修正的潜力。</p>
</div><h2><strong>Wall Street Hails Future Earnings Growth Projection</strong></h2>
<div class="lb-trans"><h2><strong>华尔街赞扬未来盈利增长预测</strong></h2>
</div><p>The five-star analyst's comment came days after CVS Health raised its guidance for Fiscal Year 2026 to wide applause from Wall Street. The health services group noted that it expects to see a compound annual growth rate (CAGR) in the mid-teens for its adjusted earnings per share (EPS) throughout 2028 — this compares more favorably with its prior 6% growth.</p>
<div class="lb-trans"><p>这位五星级分析师的评论是在 CVS Health 将 2026 财年的指引上调后几天发表的，受到华尔街的热烈欢迎。该健康服务集团指出，预计到 2028 年，其调整后每股收益（EPS）的复合年增长率（CAGR）将在中十几的水平，这与之前的 6% 增长相比更具吸引力。</p>
</div><p>The company, which is based in the U.S. state of Rhode Island, expects to build its performance on stronger margins from its businesses, led by recovery at its insurance arm Health Care Benefits (HCB).</p>
<div class="lb-trans"><p>这家公司总部位于美国罗德岛州，预计将通过其业务的更强利润率来提升业绩，主要得益于其保险部门健康护理福利（HCB）的复苏。</p>
</div><h2><strong>CVS Health Sees FY26 Revenue Below Consensus</strong></h2>
<div class="lb-trans"><h2><strong>CVS Health 预计 2026 财年收入低于市场共识</strong></h2>
</div><p>In Q3 2025, CVS Health expanded its revenue and EPS, topping Wall Street projections despite a $5.78 billion write-down. The company has said it is closing out 2025 &#34;with meaningful momentum&#34; and expects its FY26 revenue to reach $400 billion, below analysts' consensus of $418.33 billion.</p>
<div class="lb-trans"><p>在 2025 年第三季度，CVS Health 的收入和每股收益超出华尔街预期，尽管有 57.8 亿美元的减记。该公司表示，预计 2025 年将以 “显著的势头” 收尾，并预计 2026 财年收入将达到 4000 亿美元，低于分析师共识的 4183.3 亿美元。</p>
</div><p>However, focusing on CAGR projection for the EPS, Morgan Stanley analyst Erin Wright noted that the guidance was &#34;well received&#34; and is &#34;nicely ahead&#34; of previous estimates. Wright added that the pharmacy chain's 2026 guidance also fell in line with previous commentary.</p>
<div class="lb-trans"><p>然而，摩根士丹利分析师 Erin Wright 指出，专注于每股收益的 CAGR 预测，该指引 “反响良好”，并且 “明显高于” 之前的估计。Wright 补充说，该药房连锁的 2026 年指引也与之前的评论一致。</p>
</div><h2><strong>Is CVS Health a Good Stock to Buy?</strong></h2>
<div class="lb-trans"><h2><strong>CVS Health 是一个值得购买的好股票吗？</strong></h2>
</div><p>Across Wall Street, CVS Health's shares continue to carry a Strong Buy consensus rating. This is based on 17 Buys and one Hold issued by analysts over the past three months.</p>
<div class="lb-trans"><p>在华尔街，CVS Health 的股票继续获得强烈买入的共识评级。这是基于过去三个月分析师发布的 17 个买入和一个持有评级。</p>
</div><p>In addition, the average CVS price target of $95.67 implies over 22% upside potential from current trading levels.</p>
<div class="lb-trans"><p>此外，CVS 的平均目标价为 95.67 美元，意味着从当前交易水平来看有超过 22% 的上涨潜力。</p>
</div>

自今年一月以来，CVS Health 的股价已上涨 82%，并获得了华尔街对 2026 年的支持